Literature DB >> 21894179

Heart failure: Cardiac myosin activator shows promise in phase II trial.

Gregory B Lim.   

Abstract

Entities:  

Year:  2011        PMID： 21894179     DOI： 10.1038/nrcardio.2011.137

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Authors:  John G F Cleland; John R Teerlink; Roxy Senior; Evgeny M Nifontov; John J V Mc Murray; Chim C Lang; Vitaly A Tsyrlin; Barry H Greenberg; Jamil Mayet; Darrel P Francis; Tamaz Shaburishvili; Mark Monaghan; Mitchell Saltzberg; Ludwig Neyses; Scott M Wasserman; Jacqueline H Lee; Khalil G Saikali; Cyril P Clarke; Jonathan H Goldman; Andrew A Wolff; Fady I Malik
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

2.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Authors:  John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.